ONO Pharmaceutical Co. Ltd.

03/21/2024 | Press release | Distributed by Public on 03/20/2024 22:02

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line[...]

 This material is intended to notify the press release issued on March 20 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.